Volume 30, Number 9—September 2024
Research
Medical Costs of Nontuberculous Mycobacterial Pulmonary Disease, South Korea, 2015–2019
Table 6
Multiple linear regression analysis of factors driving cumulative cost in study of medical costs of nontuberculous mycobacterial pulmonary disease, South Korea, 2015–2019*
Model no., variable(s) | B | SE | β | t | p value | R2 | Adjusted R2 |
---|---|---|---|---|---|---|---|
1 | |||||||
No. admissions |
6058.547 |
627.484 |
0.785 |
9.655 |
<0.001 |
0.616 |
0.610 |
2 | 0.739 | 0.730 | |||||
No. admissions | 5503.292 | 532.913 | 0.713 | 10.327 | <0.001 | ||
Causative species: MAC = 0, M. abscessus = 1 |
7921.642 |
1530.022 |
0.358 |
5.177 |
<0.001 |
||
3 | 0.758 | 0.746 | |||||
No. admissions | 5379.334 | 520.642 | 0.697 | 10.332 | <0.001 | ||
Causative species: MAC = 0, M. abscessus = 1 | 7445.211 | 1502.260 | 0.336 | 4.956 | <0.001 | ||
Culture conversion | −3082.792 | 1455.967 | −0.142 | −2.117 | 0.039 |
*N = 147 patients. Variables include age, sex, history of tuberculosis, history of nontuberculous mycobacteria treatment, bronchiectasis, asthma, chronic obstructive pulmonary disease, lung cancer, causative species (MAC vs. M. abscessus), total follow-up duration, treatment duration, number of outpatient visits, number of admissions, culture conversion, microbiologic cure, retreatment for recurrence, and death from any cause. MAC, Mycobacterium avium complex; NA, not applicable.
1These first authors contributed equally to this article.
2These authors were co–principal investigators.